Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p
📊
Key Findings & Data:Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p
💡
Conclusion & Impact:Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters
Abstract
Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p
Özet
Amaç: Çoklu beyin metastazı olan küçük hücreli dışı akciğer kanseri hastalarında sağkalımı etkileyen faktörleri araştırmayı amaçladık. Yöntemler: 2012-2017 yılları arasında Sağlık Bilimleri Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Radyasyon Onkoloji Kliniği’nde, ilk başvuru anında veya hastalığın takibi sırasında beyin metastazı gelişen küçük hücreli dışı akciğer kanseri tanılı 130 hasta değerlendirildi. Bulgular: Tek değişkenli analizde, yaş >60 (p=0,006), tanı anında evre 4 hastalık (p
🔖
Cite This Article
İNANÇ, B., MERMUT, Ö., YARDIMCI, A. H. (2022). Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal, Cilt: 22 - Sayı: 1, 55–60. https://ajindex.com/articles/551782
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
Goncalves PH, Peterson SL, Vigneau FD, Shore RD, Quarshie WO, Islam K, et al. Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer 2016; 122: 1921-7
Villarreal-Garza C, de la Mata D, Zavala DG, Macedo-Perez EO, Arrieta O. Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. Clin Lung Cancer 2013; 14: 6-13
Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res 2015; 35: 5797-806
Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 2018; 25(Suppl 1): S103-S14
Sahgal A, Soliman H, Larson DA. Whole-brain radiation therapy of brain metastasis. Prog Neurol Surg 2012; 25: 82-95
Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012: 2012: CD003869
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-7
Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int 2013; 4(Suppl 4): S192-202
Dimitropoulos C, Hillas G, Nikolakopoulou S, Kostara I, Sagris K, Vlastos F, et al. Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates? Cancer Manag Res 2011; 3: 287-94
Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q, et al. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 2014; 89: 330‐7
Hsiao SH, Chung CL, Chou YT, Lee HL, Lin SE, Liu HE. Identification of subgroup patients with stage IIIB/IV non-small